Opus Non Current Assets Total from 2010 to 2025
| IRD Stock | 1.13 0.02 1.74% |
Non Current Assets Total | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 5.7 K |
Check Opus Genetics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Opus Genetics,'s main balance sheet or income statement drivers, such as Tax Provision of 13.1 K, Interest Expense of 0.0 or Selling General Administrative of 8.3 M, as well as many indicators such as . Opus financial statements analysis is a perfect complement when working with Opus Genetics, Valuation or Volatility modules.
Opus | Non Current Assets Total |
Latest Opus Genetics,'s Non Current Assets Total Growth Pattern
Below is the plot of the Non Current Assets Total of Opus Genetics, over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Opus Genetics,'s Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Opus Genetics,'s overall financial position and show how it may be relating to other accounts over time.
| Non Current Assets Total | 10 Years Trend |
|
Non Current Assets Total |
| Timeline |
Opus Non Current Assets Total Regression Statistics
| Arithmetic Mean | 10,625 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 53.56 | |
| Mean Deviation | 4,641 | |
| Median | 14,000 | |
| Standard Deviation | 5,691 | |
| Sample Variance | 32.4M | |
| Range | 14K | |
| R-Value | (0.79) | |
| Mean Square Error | 12.8M | |
| R-Squared | 0.63 | |
| Significance | 0.0002 | |
| Slope | (950.00) | |
| Total Sum of Squares | 485.7M |
Opus Non Current Assets Total History
About Opus Genetics, Financial Statements
Opus Genetics, stakeholders use historical fundamental indicators, such as Opus Genetics,'s Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although Opus Genetics, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Opus Genetics,'s assets and liabilities are reflected in the revenues and expenses on Opus Genetics,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Opus Genetics,. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Opus Genetics, is a strong investment it is important to analyze Opus Genetics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Opus Genetics,'s future performance. For an informed investment choice regarding Opus Stock, refer to the following important reports:Check out the analysis of Opus Genetics, Correlation against competitors. For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opus Genetics,. If investors know Opus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opus Genetics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.09) | Revenue Per Share 0.337 | Quarterly Revenue Growth (0.68) | Return On Assets (0.39) | Return On Equity |
The market value of Opus Genetics, is measured differently than its book value, which is the value of Opus that is recorded on the company's balance sheet. Investors also form their own opinion of Opus Genetics,'s value that differs from its market value or its book value, called intrinsic value, which is Opus Genetics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opus Genetics,'s market value can be influenced by many factors that don't directly affect Opus Genetics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opus Genetics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opus Genetics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.